Acadia Pharmaceuticals
SAN DIEGO, CA · CIK 0001070494 · Biotech · Public
Small-molecule pharmaceuticals for neurological disorders and rare diseases
acadiapharm.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $107M
- 2 Form D · Jan 2013
- 165 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 19 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2010201120122013
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $21,069,109 | |
| Private capital raised | Form D · SEC | $86,385,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2818 | Relation Therapeutics | — | $116M |
| 2819 | STEL Technologies, LLC | — | — |
| 2820 | Passage Bio | — | $110M |
| 2821 | Acadia Pharmaceuticals | — | $107M |
| 2822 | Neurogene Inc. | — | $106M |
| 2823 | Ovid Therapeutics | — | $106M |
| 2824 | LEAP THERAPEUTICS, INC. | — | $105M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- THOMAS AASENExecutive Officer
- GLENN BAITYExecutive Officer
- MICHAEL BORERDirector
- LAURA BREGEDirector
- MARY ANN GRAYDirector
- ULI HACKSELLDirector · Executive Officer
- LESLIE IVERSENDirector
- LESTER KAPLANDirector
- ROGER MILLSExecutive Officer
- TORSTEN RASMUSSENDirector
- WILLIAM WELLSDirector
Patents
- Neuro-attenuating Ketamine And Norketamine Compounds, Derivatives Thereof, And Methodsapplication
- Crystalline Forms Of Trofinetideapplication
- Single-layer Oral Dose Of Neuro-attenuating Ketaminegranted
- Crystalline Forms Of Trofinetidegranted
- Modulators Of G Protein-coupled Receptor 88application
- Modulators Of G Protein-coupled Receptor 88application
- Neuro-attenuating Ketamine And Norketamine Compounds, Derivatives Thereof, And Methodsgranted
- Compounds, Salts Thereof And Methods For Treatment Of Diseasesapplication
- Compounds, Salts Thereof And Methods For Treatment Of Diseasesgranted
- Modulators Of G Protein-coupled Receptor 88application
- Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseasesapplication
- Carbetocin Drug Product And Process For Preparing Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.